Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703686 | 0.94 | SMN1; SMN2 (0.43) | NPC1RAB9ASMN1; SMN2PIK3CDCYP2C19 | |
| SCHEMBL1704245 | 0.93 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2PIK3CDCYP2C19 | |
| SCHEMBL1703502 | 0.92 | PIK3CD (0.42) | NPC1RAB9ASMN1; SMN2PIK3CDPIK3CG | |
| SCHEMBL1704298 | 0.92 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2PIK3CDCYP2C19 | |
| SCHEMBL1703780 | 0.91 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2PIK3CDCYP2C19 | |
| SCHEMBL1704013 | 0.91 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2PIK3CDCYP2C19 | |
| SCHEMBL15260579 | 0.85 | PIK3CG (0.57) | NPC1RAB9ASMN1; SMN2PIK3CDPIK3CG | |
| SCHEMBL21980342 | 0.85 | PIK3CD (0.54) | NPC1RAB9ASMN1; SMN2PIK3CDPIK3CG | |
| SCHEMBL21980237 | 0.84 | PIK3CD (0.50) | NPC1RAB9ASMN1; SMN2PIK3CDPIK3CG | |
| SCHEMBL21980235 | 0.84 | PIK3CD (0.50) | NPC1RAB9ASMN1; SMN2PIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2441768-A1 | Thienopyrimidinones for treatment of inflammatory disorders and cancers | Eli Lilly & Co. (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | ICOS CORPORATION | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216820-A1 | THIENOPYRIMIDIONES FOR TREATMENT OF INFLAMMATORY DISORDERS AND CANCERS | PIK3CA, PIK3CD, PIK3CB | NPC1 3005/4885RAB9A 1996/4885SMN1; SMN2 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.